Methohexitone

• Anesthetics
• Barbiturates
• ATC:N01AF01
• ATC:N05CA15

• Brevital
• Brevital sodium
• Brietal
• Methodrexitone
• Methohexitone

• No information avaliable

C₁₄H₁₈N₂O₃

http://www.rxlist.com/cgi/generic3/methohexital.htm

Methohexitone FDA

No information avaliable

262.304 g/mol

No information avaliable

No information avaliable

Solid

1.724

Powder for solution

Indicated for use as an intravenous anaesthetic.

Methohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.

The absolute bioavailability following rectal administration of methohexital is 17%.

The onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.

When appropriate, patients should be instructed as to the hazards of drowsiness that may follow use of barbiturates. Outpatients should be released in the company of another individual, and no skilled activities, such as operating machinery or driving a motor vehicle, should be engaged in for 8 to 12 hours.

Humans and other mammals